Bluebird bio, Inc.
BLUE
株式のランク
#15676
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
株価
$4.97
最終同期: 2025-06-02
時価総額
$318.62M
変化（1日）
0.00%
変化（1年）
-38.03%
国
US
取引 Bluebird bio, Inc. (BLUE)
カテゴリー
Healthcare
Bluebird bio, Inc.（BLUE）の発行済株式数
October 2026 時点の発行済株式数 0
Bluebird bio, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。October 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Bluebird bio, Inc.（BLUE）の発行済株式数の履歴（2026 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
